• Explore /
  • Poster
  • / Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study.

Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study.

Abstract Video & Slides Poster

Authors

null

Evangelos Terpos

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Evangelos Terpos , Maria Gavriatopoulou , Ioannis Ntanasis-Stathopoulos , Panagiotis Malandrakis , Despina Fotiou , Magdalini Migkou , Foteini Theodorakakou , Vasiliki Spiliopoulou , Rodanthi Syrigou , Evangelos Eleutherakis Papaiakovou , Stavros Gkolfinopoulos , Kyriaki Manousou , Efstathios Kastritis , Meletios A. Dimopoulos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT04808037

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8050)

DOI

10.1200/JCO.2023.41.16_suppl.8050

Abstract #

8050

Poster Bd #

42

Abstract Disclosures

Similar Posters

First Author: Saad Zafar Usmani

First Author: Sebastian Grosicki

First Author: Saad Zafar Usmani

First Author: Andree Kurniawan